Patents Assigned to Demerx, Inc.
  • Patent number: 11197866
    Abstract: Methods and compositions for potentiating the effect of an opioid analgesic in a patient undergoing or planning to undergo opioid analgesic therapy using a potentiating amount of iboga alkaloid or pharmaceutically acceptable salt and/or solvate thereof that does not prolong the patient's QT interval by more than about 50 milliseconds.
    Type: Grant
    Filed: May 22, 2020
    Date of Patent: December 14, 2021
    Assignee: DEMERX, INC.
    Inventors: Holger Weis, Emeline Maillet
  • Patent number: 11077118
    Abstract: This invention provides a method for treating anxiety-related disorder or impulse control disorder, regulating food intake, attenuating food cravings, or treating anger and/or violence and disorders associated therewith in a patient, comprising administering to the patient in need thereof a therapeutically effective amount of ibogaine, ibogaine derivative, or a pharmaceutically acceptable salt and/or solvate thereof.
    Type: Grant
    Filed: March 9, 2017
    Date of Patent: August 3, 2021
    Assignee: DEMERX, INC.
    Inventor: Emeline Maillet
  • Publication number: 20200093833
    Abstract: This invention provides a method for treating anxiety-related disorder or impulse control disorder, regulating food intake, attenuating food cravings, or treating anger and/or violence and disorders associated therewith in a patient, comprising administering to the patient in need thereof a therapeutically effective amount of ibogaine, ibogaine derivative, or a pharmaceutically acceptable salt and/or solvate thereof.
    Type: Application
    Filed: March 9, 2017
    Publication date: March 26, 2020
    Applicant: DemeRX, Inc.
    Inventor: Emeline Maillet
  • Publication number: 20200085836
    Abstract: This invention is directed to a method of treating alcohol dependence, including acute and post-acute withdrawal symptoms, comprising treating an alcohol dependent patient with ibogaine, ibogaine derivative, or pharmaceutically acceptable salt and/or solvate thereof at a dosage that provides an average serum concentration of about 50 ng/mL to about 850 ng/mL under conditions where the QT interval prolongation does not exceed about 50 milliseconds.
    Type: Application
    Filed: October 23, 2017
    Publication date: March 19, 2020
    Applicant: DemeRx, Inc.
    Inventors: Emeline Maillet, Lawrence Friedhoff
  • Publication number: 20200078367
    Abstract: This invention is directed to a method of treating opioid or opioid-like drug addiction, including acute and post-acute withdrawal symptoms, comprising treating an addicted patient with ibogaine, ibogaine derivative, or pharmaceutically acceptable salt or solvate thereof at a dosage that provides an average serum concentration of about 50 ng/mL to about 850 ng/mL under conditions where the QT interval prolongation does not exceed about 50 milliseconds.
    Type: Application
    Filed: October 17, 2017
    Publication date: March 12, 2020
    Applicant: DemeRX, Inc.
    Inventor: Lawrence Friedhoff
  • Publication number: 20190262351
    Abstract: Disclosed are noribogaine compositions comprising a very high level of the 2(R), 4(S), 5(S), 6(S) and 18(R) enantiomer and not more than 0.5 wt % of ibogaine relative to the total amount of noribogaine.
    Type: Application
    Filed: June 3, 2016
    Publication date: August 29, 2019
    Applicant: DemeRx, Inc.
    Inventors: Robert M. Moriarty, Deborah C. Mash
  • Publication number: 20180319800
    Abstract: This invention provides novel (1R,4R) 7-oxo-2-azabicyclo[2.2.2]oct-5-ene and derivatives thereof, preferably in substantially enantiomerically enriched forms, intermediates thereto, and processes of their synthesis.
    Type: Application
    Filed: November 13, 2017
    Publication date: November 8, 2018
    Applicant: DemeRx, Inc.
    Inventor: Robert M. Moriarty
  • Publication number: 20180280406
    Abstract: This invention is directed to a method of treating opioid or opioid-like drug addiction, including acute and post-acute withdrawal symptoms, comprising treating an addicted patient with noribogaine at a dosage that provides an average serum concentration of about 50 ng/mL to about 180 ng/mL under conditions where the QT interval prolongation does not exceed about 50 milliseconds.
    Type: Application
    Filed: October 10, 2017
    Publication date: October 4, 2018
    Applicant: DemeRx, Inc.
    Inventor: Lawrence Friedhoff
  • Publication number: 20170368073
    Abstract: This invention is directed to methods of treating pain in patients comprising treating patients with ibogaine, an ibogaine derivative, or a pharmaceutically acceptable salt and/or solvate thereof at a therapeutic dosage that provides an average serum concentration of about 50 ng/mL to about 850 ng/mL.
    Type: Application
    Filed: February 6, 2017
    Publication date: December 28, 2017
    Applicant: DemeRX, Inc.
    Inventor: Lawrence Friedhoff
  • Publication number: 20170368074
    Abstract: This invention provides methods and compositions for treating nicotine addiction or treating or preventing nicotine cravings in a subject. The method comprises administering to the patient in need thereof a therapeutically effective amount of noribogaine, noribogaine derivative, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: February 6, 2017
    Publication date: December 28, 2017
    Applicant: DemeRx, Inc.
    Inventors: Emeline Maillet, Lawrence Friedhoff
  • Publication number: 20170354662
    Abstract: This invention provides methods and compositions for treating or preventing migraine headache and/or symptoms thereof in a subject. The method comprises administering to the subject in need thereof a therapeutically effective amount of noribogaine, noribogaine derivative, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: January 23, 2017
    Publication date: December 14, 2017
    Applicant: DemeRx, Inc.
    Inventor: Holger Weis
  • Patent number: 9744174
    Abstract: A short treatment with noribogaine shows promise for treating drug dependency. Many opioid addicts are treated with methadone. Giving noribogaine to mammal concurrently being administered methadone surprisingly exacerbates methadone's negative side-effects, and increases the risk of death. Therefore, prior to noribogaine treatment, a patient on methadone therapy undergoes a period of methadone abstinence to wash out the methadone. Surprisingly, noribogaine does not react negatively to morphine. According to the invention, methadone regimen is replaced with morphine prior to noribogaine treatment.
    Type: Grant
    Filed: June 3, 2014
    Date of Patent: August 29, 2017
    Assignee: DEMERX, INC.
    Inventor: Lawrence Friedhoff
  • Patent number: 9617265
    Abstract: Stable noribogaine salt ansolvates are useful for preparing pharmaceutical compositions and for alleviating nociceptive pain in a patient. Such ansolvates can be prepared by slurrying solvated forms, preferably MeOH solvated noribogaine hydrochloride in EtOH/water.
    Type: Grant
    Filed: May 23, 2015
    Date of Patent: April 11, 2017
    Assignee: DEMERX, INC.
    Inventors: Richard D. Gless, Jr., William C. Schinzer
  • Patent number: 9617274
    Abstract: Synthetic noribogaine preferably free of ibogaine and, optionally, one or more of other naturally occurring Tabernanth iboga alkaloids, is provided.
    Type: Grant
    Filed: March 2, 2015
    Date of Patent: April 11, 2017
    Assignee: DEMERX, INC.
    Inventors: Robert M. Moriarty, Richard D. Gless, Jr.
  • Patent number: 9592239
    Abstract: This invention provides a method for treating anxiety-related disorder or impulse control disorder, regulating food intake, attenuating food cravings, or treating anger and/or violence and disorders associated therewith in a patient, comprising administering to the patient in need thereof a therapeutically effective amount of ibogaine, ibogaine derivative, or a pharmaceutically acceptable salt and/or solvate thereof.
    Type: Grant
    Filed: March 2, 2015
    Date of Patent: March 14, 2017
    Assignee: DEMERX, INC.
    Inventor: Emeline L. Maillet
  • Patent number: 9591978
    Abstract: This invention is directed to a method for pre-screening an opioid-addicted patient to determine the patient's tolerance for a therapeutic dose of noribogaine.
    Type: Grant
    Filed: February 17, 2015
    Date of Patent: March 14, 2017
    Assignee: DEMERX, INC.
    Inventor: Lawrence Friedhoff
  • Patent number: 9586954
    Abstract: This invention relates generally to prodrugs of noribogaine. This invention also relates to pharmaceutical compositions comprising the prodrugs of noribogaine as well as method of treating pain, addiction and/or stress using such compounds and/or pharmaceutical compositions.
    Type: Grant
    Filed: April 21, 2014
    Date of Patent: March 7, 2017
    Assignee: DEMERX, INC.
    Inventor: Deborah C. Mash
  • Patent number: 9561233
    Abstract: This invention is directed to methods of treating pain in patients comprising treating patients with ibogaine, an ibogaine derivative, or a pharmaceutically acceptable salt and/or solvate thereof at a therapeutic dosage that provides an average serum concentration of about 50 ng/mL to about 850 ng/mL.
    Type: Grant
    Filed: March 2, 2015
    Date of Patent: February 7, 2017
    Assignee: DEMERX, INC.
    Inventor: Lawrence Friedhoff
  • Patent number: 9561232
    Abstract: This invention provides methods and compositions for treating nicotine addiction or treating or preventing nicotine cravings in a subject. The method comprises administering to the patient in need thereof a therapeutically effective amount of noribogaine, noribogaine derivative, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: February 17, 2015
    Date of Patent: February 7, 2017
    Assignee: DEMERX, INC.
    Inventors: Emeline Maillet, Lawrence Friedhoff
  • Publication number: 20170022194
    Abstract: Stable noribogaine salt ansolvates are useful for preparing pharmaceutical compositions and for alleviating nociceptive pain in a patient. Such ansolvates can be prepared by slurrying solvated forms, preferably MeOH solvated noribogaine hydrochloride in EtOH/water.
    Type: Application
    Filed: October 7, 2016
    Publication date: January 26, 2017
    Applicant: DemeRx, Inc.
    Inventors: Richard D. Gless, JR., William C. Schinzer